Quantitative Measurement of Plasma and Urine MTB Cell-free DNA Level

NCT ID: NCT07170735

Last Updated: 2025-12-30

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Total Enrollment

85 participants

Study Classification

OBSERVATIONAL

Study Start Date

2026-01-01

Study Completion Date

2027-06-30

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Tuberculosis (TB) is one of the leading causes of infectious disease worldwide. The diagnosis of TB typically relies on microbiological evidence of the presence of Mycobacterium tuberculosis (MTB) or histological features of the host immune response to MTB in the infected organs. The diagnosis can be enhanced by performing molecular diagnostic tests (e.g. polymerase chain reaction, PCR) on the clinical specimens obtained. Expectorated sputum is usually the first sample sent for MTB culture for suspected pulmonary TB (PTB), which is the most common type of TB. However, this can be particularly challenging for paediatric patients and elderly patients with poor coughing techniques or effort. While for extrapulmonary TB (EPTB), which contributes to 10-20% of TB cases, with TB pleuritis and lymphadenitis as the most common types, invasive investigations are usually required for obtaining clinical specimens of good quality for MTB culture or histological examination. The invasiveness of procedures (e.g. pleural biopsy, lymph node biopsy) and inadequate sensitivity of diagnostic tests could hinder the diagnosis of EPTB. The long turnaround time of MTB culture also creates a challenge for timely diagnosis. Blood sampling for MTB culture or PCR, although non-invasive, has low diagnostic yields. All these urges for non-invasive, rapid and accurate diagnosis of TB.

The standard duration of TB treatment is 6 months, with a longer duration up to 12 months required for certain types of EPTB or in patients with underlying comorbidities (e.g. diabetes mellitus). Treatment monitoring and surveillance for relapses are typically based on a composite of clinical symptoms, sputum MTB culture status, and radiographical appearance. All these domains have their drawbacks, including subjective reporting (clinical symptoms), long turnaround times (sputum MTB culture status), and a lack of diagnostic sensitivity (changes in radiographical appearance in PTB). These clinical unmet needs may be overcome if a non-invasive molecular test could accurately quantify the burden of MTB in the body. Recently, it was reported that the level of MTB cfDNA in plasma can be measured by the CRISPR-TB assay. However, the data were derived mainly from the paediatric patient group and did not evaluate the possibility of latent TB infection (LTBI). This new technology remains explorative at the moment.

Our group has developed a metagenomic sequencing-based assay for measuring the level of MTB cell-free DNA (cfDNA) in plasma. We hypothesize that this new plasma MTB cfDNA assay has the potential to diagnose active TB disease, treatment monitoring and surveillance monitoring by serially measuring the MTB cfDNA level in the plasma. Similar technology may also be applicable to urine, which requires prospective validation.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Tuberculosis

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

Tuberculosis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

COHORT

Study Time Perspective

PROSPECTIVE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TB group

patients with active TB disease

Plasma MTB cfDNA assay

Intervention Type DIAGNOSTIC_TEST

Quantitative measurement of MTB cfDNA level in the plasma

Urine MTB cfDNA assay

Intervention Type DIAGNOSTIC_TEST

Quantitative measurement of MTB cfDNA level in the urine

LTBI group

patients with latent TB infection

Plasma MTB cfDNA assay

Intervention Type DIAGNOSTIC_TEST

Quantitative measurement of MTB cfDNA level in the plasma

Urine MTB cfDNA assay

Intervention Type DIAGNOSTIC_TEST

Quantitative measurement of MTB cfDNA level in the urine

control group

subjects without active TB disease or latent TB infection

Plasma MTB cfDNA assay

Intervention Type DIAGNOSTIC_TEST

Quantitative measurement of MTB cfDNA level in the plasma

Urine MTB cfDNA assay

Intervention Type DIAGNOSTIC_TEST

Quantitative measurement of MTB cfDNA level in the urine

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Plasma MTB cfDNA assay

Quantitative measurement of MTB cfDNA level in the plasma

Intervention Type DIAGNOSTIC_TEST

Urine MTB cfDNA assay

Quantitative measurement of MTB cfDNA level in the urine

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* TB group: patients hospitalized for newly diagnosed TB disease.
* LTBI group: patients without TB disease, but with LTBI diagnosed by either tuberculin skin test (TST) or an interferon-gamma release assay (IGRA) blood test.
* Control group: patients or healthy volunteers without TB disease and LTBI

Exclusion Criteria

* History of prior TB disease.
* Concomitant use of at least two first-line anti-TB drugs for at least 2 weeks in the past 3 months.
* Aged 17 years or younger
* Life expectancy of less than 12 months
* Failed to obtain informed consent due to the patient's refusal or cognitive impairment
Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Chinese University of Hong Kong

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Ka Pang Chan

Assistant Professor

Responsibility Role PRINCIPAL_INVESTIGATOR

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Prince of Wales Hospital

Hong Kong, Hong Kong, Hong Kong

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Hong Kong

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ka Pang Chan, MBChB

Role: CONTACT

Phone: 35052211

Email: [email protected]

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Ka Pang Chan, MBChB

Role: primary

Karen Yiu

Role: backup

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

LIQUID-MTB

Identifier Type: -

Identifier Source: org_study_id